Article information
Abstract
Objective
Because epidemiological data on circulating HIV subtypes among HIV-positive patients in the state of Paraná were not known until now, the aims of this study were to describe the genetic diversity profile of HIV-1 in treated patients in Paraná, Brazil, and report the differences in protease (PR) and reverse transcriptase (RT) mutations in HIV-1 subtypes.
Patients and methodsA cross-sectional study was conducted from 2003 to 2006. Plasma viral RNA of 389 patients was extracted and PR and RT genes were polymerase chain reaction-amplified and sequenced. Sequences were subtyped and examined for antiretroviral resistance mutations. Data on gender of patient harboring the viruses and past history of antiretroviral treatment were also collected.
ResultsMost viruses were either subtype B (61.44%) or subtype C (20.57%). Subtype C and F were more frequent in women (p < 0.00). The prevalence of subtypes was similar over the years studied. The most frequent RT mutations in all subtypes were M184V and mutations at codons 215, 41, 103, 67, 219, and 190. Mutations 41L, 210W, 215YF, and 74V were significantly more prevalent on subtype B, and the mutation 106M was significantly more prevalent on subtype C. The most frequent major PI mutations in all subtypes occurred at codons 46, 82, and 90. PR mutations 32I, 46I, and 84V were significantly more prevalent on subtype B. The minor PI mutations on codons 36, 93, and 63 were more prevalent on subtypes F, C, and B, respectively.
ConclusionWe concluded that the predominant strain of HIV-1 in Paraná is subtype B, followed by subtype C. Some mutations at PR and TR had subtype predominance in accordance with other authors’ report.
Keywords:
HIV-1 subtypes
genotype
antiretroviral
drug experienced patients
Full text is only aviable in PDF
References
[1.]
B.H. Hahn, G.M. Shaw, S.K. Arya, M. Popovic, R.C. Gallo, F. Wong-Staal.
Molecular cloning and characterization of the HTLV-III virus associated with AIDS.
Nature, 312 (1984), pp. 166-169
[2.]
D.L. Robertson, J.P. Anderson, J.A. Bradac, et al.
HIV-1 nomenclature proposal.
Science, 288 (2000), pp. 55-56
[3.]
D.L. Robertson, P.M. Sharp, F.E. McCutchan, B.H. Hahn.
Recombination in HIV-1.
Nature, 374 (1995), pp. 124-126
[4.]
J.T. Blackard, D.E. Cohen, K.H. Mayer.
Human immunodeficiency virus superinfection and recombination: current state of knowledge and potential clinical consequences.
Clin Infect Dis, 34 (2002), pp. 1108-1114
[5.]
Los Alamos National Laboratory. HIV Sequence database. [http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html] 2007.
[6.]
B. Korber, B. Gaschen, K. Yusim, R. Thakallapally, C. Kesmir, V. Detours.
Evolutionary and immunological implications of contemporary HIV-1 variation.
Br Med Bull, 58 (2001), pp. 19-42
[7.]
M.J. Gonzales, R.N. Machekano, R.W. Shafer.
Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a Northern California clinic-based population.
J Infect Dis, 184 (2001), pp. 998-1006
[8.]
M. Wainberg.
HIV-1 subtype distribution and the problem of drug resistance.
AIDS, 18 (2004), pp. S63-S68
[9.]
M.A. Soares, T. De Oliveira, R.M. Brindeiro, et al.
A specific subtype C of human immunodeficiency virus type 1 circulates in Brazil.
AIDS, 17 (2003), pp. 11-21
[10.]
E.A. Soares, R.P. Santos, J.A. Pellegrini, E. Sprinz, A. Tanuri, M.A. Soares.
Epidemiologic and molecular characterization of human immunodeficiency virus type 1 in Southern Brazil.
J Acquir Immune Defic Syndr, 34 (2003), pp. 520-526
[11.]
E.A. Soares, A.M. Martínez, T.M. Souza, et al.
HIV-1 subtype C dissemination in southern Brazil.
AIDS, 19 (2005), pp. S81-S86
[12.]
E.A. Soares, A.F. Santos, T.M. Sousa, et al.
Differential Drug Resistance Acquisition in HIV-1 of Subtypes B and C.
PloS One, 2 (2007), pp. e730
[13.]
J.L.P. Ferreira, M. Thomaz, R. Rodrigues, et al.
Molecular characterisation of newly identified HIV-1 infections in Curitiba. Brazil: preponderance of clade C among males with recent infections.
Mem Inst Oswaldo Cruz, 103 (2008), pp. 800-808
[14.]
R.M. Brindeiro, R.S. Diaz, E.C. Sabino, et al.
Brazilian Network for Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals.
AIDS, 17 (2003), pp. 1063-1069
[15.]
E.C. Sabino, E.G. Shpaer, M.G. Morgado, et al.
Identification of human immunodeficiency virus type 1 envelope genes recombinant between subtypes B and F in two epidemiologically linked individuals from Brazil.
J Virol, 68 (1994), pp. 6340-6346
[16.]
J.C. Couto-Fernandez, C. Silva-de-Jesus, V.G. Veloso, et al.
Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro. Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.
Mem Inst Oswaldo Cruz, 100 (2005), pp. 73-78
[17.]
D.J. de Sa-Filho, M.S. Soares, V. Candido, et al.
HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in Santos.
Brazil. AIDS Res Hum Retroviruses, 24 (2008), pp. 347-353
[18.]
A.T. Dumans, C.C. Barreto, A.F. Santos, et al.
Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virologic failure.
Infect Genet Evol, 9 (2009), pp. 62-70
[19.]
P. Kantor, D.A. Katzenstein, B. Efron, et al.
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration.
PLoS Med, 2 (2005), pp. e112
[20.]
A. Johnson, F. Brun-Vezinet, B. Clotet, et al.
Update of the Drug Resistance Mutations in HIV-1: Spring 2008.
Top HIV Med, 16 (2008), pp. 62-68
[21.]
C.S. Alexander, B. Montessori, W. Dong, et al.
Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia.
Antivir Ther, 7 (2002), pp. 31-35
[22.]
A.J. Frater, A. Beardall, K. Ariyoshi, et al.
Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients.
AIDS, 15 (2001), pp. 1493-1502
[23.]
L. Bocket, A. Cheret, S. Deuffic-Burban, et al.
Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness.
Antivir Ther, 10 (2005), pp. 247-254
[24.]
W.P. Bannister, L. Ruiz, C. Loveday, EuroSIDA Study Group, et al.
HIV-1 subtypes and response to combination antiretroviral therapy in Europe.
Antivir Ther, 11 (2006), pp. 707-715
[25.]
K. Champenois, S. Deuffic-Burban, L. Cotte, et al.
Natural polymorphisms in HIV-1 protease: impact on effectiveness of a first-line lopinavir-containing antiretroviral therapy regimen.
J Med Virol, 80 (2008), pp. 1871-1879
[26.]
M. Salemi, T. de Oliveira, M.A. Soares, O. Pybus, A.T. Dumans, et al.
Different epidemic potentials of the HIV-1B and C subtypes.
J Mol Evol, 60 (2005), pp. 598-605
[27.]
S.Y. Rhee, W.J. Fessel, A.R. Zolopa, et al.
HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance.
J Infect Dis, 192 (2005), pp. 456-465
[28.]
A.T. Dumans, M.A. Soares, E.S. Machado, et al.
Synonymous genetic polymorphisms within Brazilian Human Immunodeficiency Virus Type 1 Subtypes may influence mutational routes to drug resistance.
J Infect Dis, 189 (2004), pp. 1232-1238
[29.]
A.M. Cavalcanti, H.R. Lacerda, A.M. Brito, S. Pereira, D. Medeiros, S. Oliveira.
Antiretroviral resistance in individuals presenting therapeutic failure and subtypes of the human immunodeficiency virus type 1 in the Northeast Region of Brazil.
Mem Inst Oswaldo Cruz, 102 (2007), pp. 785-792
[30.]
D.A. van de Vijver, A.M. Wensing, G. Angarano, et al.
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes.
J Acquir Immune Defic Syndr, 41 (2006), pp. 352-360
[31.]
E. Caride, R. Brindeiro, K. Hertogs, et al.
Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.
Virology, 275 (2000), pp. 107-115
[32.]
Z. Grossman, V. Istomin, D. Averbuch, Israel AIDS Multi- Center Study Group, et al.
Genetic variation at NNRTI resistanceassociated positions in patients infected with HIV-1 subtype C.
AIDS, 18 (2004), pp. 909-915
[33.]
B. Brenner, D. Turner, M. Oliveira, et al.
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers crossresistance to non-nucleoside reverse transcriptase inhibitors.
AIDS, 17 (2003), pp. F1-F5
[34.]
H.R. Lacerda, L.B. Medeiros, A.M. Cavalcanti, R.A. Ximenes, M.F. Albuquerque.
Comparison of the epidemiology, profile of mutations, and clinical response to antiretrovirals among subtypes B and F of the human immunodeficiency virus type 1.
Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, 102 (2007), pp. 693-699
[35.]
E. Caride, K. Hertogs, B. Larder, et al.
Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART.
Virus genes, 23 (2001), pp. 193-202
[36.]
Z. Grossman, E.E. Paxinos, D. Averbuch, et al.
Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.
Antimicrob Agents Chemother, 48 (2004), pp. 2159-2165
Copyright © 2010. Elsevier Editora Ltda.. All rights reserved
